Reduction of blast-colony forming cell development and bi-potential commitment by neutralizing TGF-beta1 in vitro.
- Author:
Hui-Yu YAO
1
;
Bing LIU
;
Xiao-Yan WANG
;
Ning MAO
Author Information
1. Department of Molecular Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cell Differentiation;
drug effects;
Cells, Cultured;
Colony-Forming Units Assay;
Embryonic Stem Cells;
cytology;
Hematopoiesis;
physiology;
Mice;
Neovascularization, Physiologic;
physiology;
Transforming Growth Factor beta1;
antagonists & inhibitors
- From:
Journal of Experimental Hematology
2007;15(2):324-327
- CountryChina
- Language:Chinese
-
Abstract:
To study the regulation of TGF-beta(1) on the development of hemangioblast, embryonic stem cell-derived blast forming cells (BL-CFC) were used as the model of hemangioblast in vitro. TGF-beta(1) or anti-TGF-beta(1) neutralization antibody was added in the medium of embryoid body (EB) generation for observating influence of TGF-B(1) addition in different culture stages on number of BL-CFC and differentiation of BL-CFC to endothelial and hematopoietic cells. The results showed that antagonizing TGF-beta(1) in the course of EB growth could significantly reduce the number of BL-CFC (P<0.01), and the frequency of Flk-1(+) cells was also decreased consistently. Furthermore, the BL-CFC derived from EB pretreated with TGF-beta(1) demonstrated remarkably elevated hematopoietic and endothelial potential, whereas such bi-potential was impaired in the group with neutralizing antibody. It is concluded that TGF-beta(1), a conventional negative regulator in hematopoiesis and angiogenesis exert positive effects on the development and differentiation capacities of BL-CFC in vitro.
